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1. Introduction 
Gene therapy may be described as the use of genes as medicines to treat disease, or, more 
precisely, as the delivery of nucleic acids by means of vectors to patients for some 
therapeutic purpose (Thanou, M. et al., 2007). The major goal of gene therapy is to introduce 
a functional gene into a target cell and restore protein production that is absent or deficient 
due to a genetic disorder (Neeltje, A. et al., 2003). This approach is a potentially powerful 
method for the treatment of diseases for which classical pharmacotherapy is unavailable or 
not easily applicable.  
Gene therapy is a therapeutic modality with enormous promise, which is also considered to 
have failed to deliver much of therapeutic significance in spite of all the apparent clinical 
interest. Clinical trial activity in gene therapy began in 1989, peaked in 1999, and is now 
currently declining (Thanou, M. et al., 2007). This decline was marked by some clinical trial 
problems, including a death from toxic liver shock during an adenovirus-based clinical trial 
in 1999 (Marshall, E., 2000), the anomalous appearance of a transgene in the gonads during 
adeno-associated virus-based preclinical trials in 2001 (Arruda, V. R. et al., 2001), signs of 
hypertension in lipofection clinical trials in 2005 (Pro-1) (MacLachlan, I. et al., 1999), and the 
development of leukemia in retrovirus-based clinical trials for ex vivo treatment of X-linked 
severe combined immunedeficiency (X-linked SCID) (Cavazzana-Calvo, M. et al., 2004; 
Gaspar, H. B., & Thrasher, A. J., 2005). 
Lessons from those frustrated results suggest that more basic research is required in gene 
therapy study, including mechanism of diseases and features of viral vectors. In order to 
modify a specific cell type or tissue, the therapeutic gene must be efficiently delivered to the 
cell, so that it will express at the appropriate level for a sufficient duration. Thus, identifying 
the ideal means of carriage for viral gene therapy is the key rate-limiting step in the 
development of most promising gene therapy strategies. In spite of long-term and extensive 
efforts to develop in vivo gene delivery systems, little achievements have been reported, 
especially as far as clinical applications are concerned. Apparently, the development of gene 
delivery systems will be one of the most critical issues for the success of in vivo gene 
therapy.  
Over the years, two broad approaches have been used to deliver therapeutic genes to cells, 
viral vectors and non-viral vectors. These two kinds of vectors are different as regard to 
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efficiency, ease of production and safety. Preclinical and current clinical trial data suggest 
that non-viral vector systems are much less affected by immunogenicity, toxicity, and 
oncogenicity. However, the lack of delivery efficacy and short-term expression in in vivo also 
pose their greatest drawback.  
By contrast, viral-based vectors are feasible for modification and long-term gene expression, 
meanwhile, they are characterized by their infectivity and satisfactory targeting, all of which 
make them even more attractive as gene delivery systems. Nowadays, many viral vectors 
have been developed and frequently used in the present gene therapy studies, such as 
Adenovirus, Adeno-associated virus, retroviruses, herpes simplex virus type 1 and vaccinia 
virus. The real success has been reported with a serotype 5 adenovirus vector delivering the 
p53 tumor suppressor gene (Gendicine, the World’s first commercial gene therapy product, 
licensed for use in China) (Pearson S. et al., 2004). Viral vectors have also been applied in the 
treatment of monogenic diseases. In 2000, the World’s first curative gene therapy trial was 
reported after bone marrow cells were isolated from patients with X-linked SCID 
(Cavazzana-Calvo, M. et al, 2000). In a word, gene therapy with viral vectors has been 
proven effective in a variety of model systems.  
However, studies have also shown that even if some common characteristics exist, an 
important variability is introduced by the administration route, the promoter and other key 
components of the construct (targeting modifications, etc) (Dani, S.U., 1999). The variability 
results in a variety of challenges, including circumvention of immune responses against viral 
vectors and difficulty in transferring the genes to a sufficient number of cells to change the 
phenotype, and in controlling the expression of the gene (Worgall, S. & Crystal, R.G., 2007). 
Thus, it is currently admitted that pharmacokinetic studies should be carried out prior to any 
clinical trial for a promising viral gene therapy. Additionally, preexisting knowledge about the 
viral vectors, including the viral vector titration standardization issues, specific formulation 
and purification process, also prompts for dedicated pharmacokinetic studies. 
Therefore, this chapter reviews the general strategies of the pharmacokinetic studies in viral 
gene therapy, provides an overview of the pharmacokinetic characteristics of viral vectors 
and the methods used in pharmacokinetic analysis of viral gene therapy, details the 
challenges and discusses the strategies being used to improve the analytical modality in 
viral gene therapy.  
2. Pharmacokinetic characteristics of viral vectors  
Viral vectors currently available for gene therapy can roughly be categorized into 
integrating and non-integrating vectors. Vectors based on adeno-associated virus and 
retroviruses (including lentivirus and foamy virus) are classified as integrating vectors as 
they have the ability to integrate their viral genome into the chromosomal DNA of the host 
cells, which will possibly achieve lifelong gene expression. Vectors based on adenovirus 
(Ad), modified vaccinia virus of Ankara (MVA) and herpes simplex virus type 1 (HSV-1) 
represent the non-integrating vectors (Pfeifer, A. & Verma, I.M., 2001). These vectors deliver 
their genomes into the nucleus of the target cells, where they remain episomal. The different 
behavior between these two kinds of viruses will frequently determine their difference in 
the availability at the target cells and also the undesirable sites following in vivo 
administration. 
Accordingly, principles of pharmacokinetic study are equally applicable to conventional 
small-molecule drugs and biotech drugs (Meibohm, B., 2006), including viral vectors. 
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However, viral vectors often exhibit unique pharmacokinetic properties that are different 
from others. 
As described previously, replication-deficient viral vectors remain in vivo for a temporal 
period due to rapidly elimination through degradation as well as by the clearance (Senoo, 
M., et al, 2000; Hackett, N.R., et al, 2000). Usually, the elimination of viral vectors within 
tissues or within the blood compartment results from the action of both endonucleases and 
exonucleases (Goncalves, MA. et al., 2002). Hence, viral nucleic acids must be extracted and 
detected as soon as possible when performing a pharmacokinetic study with PCR method in 
case of rapid degradation. However, the suitability or yield of nucleic acid from extraction 
procedures can vary depending on the nucleic acid and the biological material (Kok, T. et al., 
2000). Great differences were found on the recoveries of viral DNA between tissues and 
blood as shown in Table 1, most experiments produced recovery of greater than 50%, while 
some were relative low but stable. Interestingly, the lowest recovery was found in blood 
(Lovatt, A., 2002). Therefore, efficient extraction of target nucleic acid should be evaluated 
for the particular target and biological material to be used. 
 
Animal tissue Recovery (%) 
Brain 60-90 
Kidney 70-95 
Spleen 68-80 
Lung 50-75 
Gonads 60-90 
Muscle 10-40 
Blood 10-20 
Heart 70-100 
Lymph node 30-90 
Liver 65-100 
Table 1. Recovery of 10~100 copies of viral nucleic acid target per 100 microgram of animal 
tissue extracted with the Qiagen DNA mini kit (tissue and blood protocol)Additionally, it is 
very important to determine the optimal blood compartment for quantitative measurement 
of virus in peripheral blood specimens. Perlman, J. et al. compared the use of whole blood 
(WB), plasma, and peripheral blood mononuclear cells (PBMC) for the detection of 
adenovirus in peripheral blood specimens from a pediatric HSCT recipient population,  
and higher viral loads were in WB and plasma than in PBMC (Perlman, J. et al., 2007).  
In viral gene therapy, gene expression and duration is an important criterion and controlled 
by the choice of promoter, CpG content, topological form of DNA etc. Although viral 
vectors are structurally similar to the wild-type progenitor virus, they generally lack some 
or all of the viral genes, so that their ability to replicate is frequently impeded or obliterated 
(Worgall, S. & Crystal, R.G., 2007). Hence, the lack of sustained transgene expression may be 
another important characteristic of viral vectors, and must be taken into account when 
setting up treatment regiments and investigating their pharmacokinetics. What’s more, 
controlling the gene expression is a challenge that needs to be addressed.  
Ideally, each delivery problem should be assessed in the round from the site of 
administration to target cells of interest. And viral vectors probably present a much greater 
risk of oncogenicity, particularly retroviral vectors that mediate insertion into actively 
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expressing gene loci, thereby creating a high risk of oncogenesis (Pfeifer, A. & Verma, I.M., 
2001). This condition must be considered during pharmacokinetic studies.  
In short, gene therapy should be seen as a somatic medicine that seeks to treat disease at a 
more fundamental level than most other therapeutic modalities are capable of. In this field, 
viral vectors have been extremely attractive as delivery system. An understanding of the 
pharmacokinetic behavior of these vectors will be utmost important when designing an 
effective therapeutic regimen, also will provide a comprehensive review of viral vectors and 
stimulate novel approaches to improve their pharmacokinetics. 
3. Methods used in pharmacokinetic evaluation of viral vectors 
As for pharmacokinetic study of viral vectors in gene therapy, the appropriate methods are 
of vital importance. With the development of science and technology, there have been many 
advances in the field of pharmacokinetic study in viral gene therapy. Many approaches have 
been developed over the past decades, especially in the utilization of molecular strategies 
for the detection and quantification of viral vectors.  
3.1 Radioactive tracers 
Radioactive tracers are compounds containing one or more radioactive atoms that allow for 
easy detection and measurement. Tracers are frequently used to track the localization of a 
specific compound or to trace the path of a compound through a series of chemical 
reactions. A number of different radioactive forms of hydrogen, carbon, phosphorus, sulfur, 
and iodine are commonly used in biochemical assays, metabolism studies, and medical 
diagnostics (Rennie M., 1999).  
A radioactive tracer is identical in chemical composition to the compound of interest and is 
administered in minute amounts that do not perturb the experimental system. The tracer 
behaves in exactly the same way as an unlabeled molecule, but the tracer molecule 
continually gives off radiation that can be detected with a Geiger counter, scintillation 
counter or other type of radiation detection instrument. Zinn K.R. et al. labeled recombinant 
adenovirus serotype 5 knob with the gamma emitter 99mTc (Zinn, K.R. et al., 1998). Maarten 
ter Horst et al. also used 99mTc to track the distribution of adenoviral vector (Maarten ter 
Horst et al., 2006). Studies suggest that this technology is sensitive and the radiolabeling 
process had no effect on receptor binding. However, it is not available in clinic research 
because the tracers will give off radiation and labs specific for isotope detection are 
required, which limits its application in research.  
3.2 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR), developed in 1983 by Kary Mullis, is a scientific 
technique to amplify a single or a few copies of a piece of DNA across several orders of 
magnitude, generating thousands to millions of copies of a particular DNA sequence 
(Bartlett & Stirling, 2003). It is now a common and usually indispensable technique used in 
medical and biological research for a variety of applications, including DNA cloning for 
sequencing, DNA-based phylogeny, functional analysis of genes, identification of genetic 
fingerprints, and diagnosis of diseases (Saiki, RK. et al., 1988; Glorioso J.C. et al., 1995). A few 
years ago, the main approach was defining generic biodistribution properties of viral 
vectors by designing studies often relying on transgene expression and mostly nonvalidated 
PCR techniques.  
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This method has greatly advanced the development of viral gene therapy and progressively 
helped defining important features of these vectors. But it is just a semi-quantification 
technology with critical problems, including the number of replicates, the necessity of an 
internal control, the specificity and the carryover contamination during sample treatment. 
Besides, the limit of quantification is not as sensitive as expected. In our study, the detection 
limit of Ad DNA was 10,000 copies per microliter (Figure.1, data unpublished), which 
greatly hampers the utility of PCR technology in DNA detection when the concentration of 
DNA in the sample is less than the level mentioned above.  
 
             NTC        101           102          103            104              105            106             107         DL2000 
 
Fig. 1. Validation of the limit of detection of PCR.  
Concentrations of DNA in reactions range from 107~101 copies per microliter. 
3.3 Southern blotting 
Southern blot, developed by Edwin Southern at Edinburgh University in the 1975, allows 
investigators to determine the molecular weight of a restriction fragment, to measure 
relative amounts in different samples and to locate a particular DNA sequence within a 
complex mixture. In this method, DNA (genomic or other source) is digested with a 
restriction enzyme, separated by gel electrophoresis and transferred from the agarose gel 
onto a membrane. The membrane is then incubated with a probe, a single-strand DNA 
labeled either radioactively or enzymatically (e.g. alkaline phosphatase or horseradish 
peroxidase), which will form a double-strand DNA with its complementary DNA sequence. 
Finally, the location of the probe is detected by directly exposing the membrane to X-ray 
film or chemiluminescent methods. Southern blotting had ever played an important role in 
viral gene therapy. Henderson Y.C. et al developed a method for detecting adenovirus in 
serum and urine with Southern Blot. Ponnazhagan S. et al used it to evaluate Ad2 in 
nonpermissive human cells (Ponnazhagan S. et al., 1995). Cichon G et al. and Bernt KM et al. 
also applied it to investigate gene therapy with adenovirus vectors (Cichon G. et al., 1999; 
and Bernt K.M. et al., 2003). Those studies suggest its high sensitivity, reproducibility and 
specificity. However, this method requires a long time and careful manipulation to avoid 
contamination. 
3.4 Western blot 
Western blot, developed by W. Neal Burnette from the laboratory of George Stark at 
Stanford, is an effective and useful method to detect and characterize proteins in small 
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amounts. In this protocol, gel electrophoresis is used to separate proteins by length of the 
polypeptide (denaturing conditions) or by the 3-D structure of the protein (native/ non-
denaturing conditions). The proteins are then transferred to a membrane (typically 
nitrocellulose or PVDF), where they are probed using antibodies specific to the target 
protein. This technique is usually used to evaluate the distribution of vectors by detecting 
expression of target genes in tissues and demonstrates high specificity and sensitivity, 
therefore, has been widely used in viral gene therapy. Fanxia Shen et al. applied it to 
evaluate hypoxia-inducible vascular endothelial growth factor gene expression mediated by 
adeno-associated viral vector- in mice (Shen FX, et al., 2006).  
3.5 Immunohistochemistry 
Immunohistochemistry (IHC) refers to the process of detecting antigens (e.g., proteins) in 
cells of a tissue section by exploiting the principle of antibodies binding specifically to 
antigens in biological tissues (RAMOS-VARA J. A., 2005). ICH staining is widely used in the 
diagnosis of abnormal cells such as those found in cancerous tumors. Specific molecular 
markers are characteristic of particular cellular events such as proliferation or cell death 
(apoptosis). IHC is also widely used in basic research to understand the distribution and 
localization of biomarkers and differentially expressed proteins in different parts of a 
biological tissue. Visualising an antibody-antigen interaction can be accomplished in a 
number of ways. In the most common instance, an antibody is conjugated to an enzyme 
such as peroxidase that can catalyse a colour-producing reaction. Alternatively, the antibody 
can also be tagged to a fluorophore, such as fluorescein or rhodamine (Elias J.M., 2003). 
This method could provide precise information about the distribution of target proteins. 
However, there are several potential problems that will affect the outcome of the procedure. 
Although antibodies show preferential avidity for specific epitopes, endogenous biotin or 
reporter enzymes or primary/secondary antibody cross-reactivity are common causes of 
strong background staining that can mask the detection of the target antigen, while weak 
staining may be caused by poor enzyme activity or primary antibody potency. Furthermore, 
autofluorescence may be due to the nature of the tissue or the fixation method (Grizzle W.E. 
et al., 2001). 
3.6 Real-time quantitative polymerase chain reaction (Q-PCR) 
The idea to monitor the PCR reaction in the thermal cycler as it progresses was first realized 
by Higuchi and colleagues in 1992 (Higuchi R. et al., 1992). And the first commercial 
platform was the Applied Biosystems ABI Prism 7700 Sequence Detection System, followed 
by the Idaho Technology LightCycler (Wittwer C.T. et al., 1997). The principle of Q-PCR is 
based on monitoring of a fluorescent signal arising during the amplification process. In this 
technique two methods are used to obtain fluorescent signals from the PCR products (Fig. 
2). One method involves the use of DNA- specific intercalating dyes such as SYBR Green I 
and the other is to use fluorescent resonance energy transfer (FRET) such as TaqMan® 
probes (Didenko V.V., 2001). 
Q-PCR has revolutionised the detection and quantification of nucleic acid due to its 
improved rapidity, sensitivity, reproducibility, reduced risk of carry-over contamination, 
and ability to quantify viral nucleic acid directly from samples (Morris T. et al., 1996; Lovatt 
A. et al., 1999; Nitsche A. et al., 1999). As a result, real-time PCR assays, as an attractive tool 
for precise evaluation of nucleic acid, have received wider acceptance than conventional 
PCR assays in the field of gene therapy.  
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Fig. 2. Two methods used to obtain fluorescent signals from the PCR products. 
(A) SYBR Green I; (B) TaqMan® probes. 
Quantification of viral vectors by a TaqMan real-time PCR assay has been previously 
reported. Our team employed TaqMan real-time PCR system to investigate the dynamics of 
Ad5-LFA-3/IgG1 by measuring its concentration in the blood of rhesus macaques and 
organs of rats (Xu XX et al., 2009).  Miyazawa N. et al. examined the kinetics of adenovirus 
genomic DNA delivery to the nucleus by measuring viral DNA with TaqMan-PCR 
(Miyazawa N. et al., 1999). Senoo M. et al. assessed the tissue distribution of recombinant 
adenovirus in mice and guinea pigs via TaqMan-PCR (Senoo M., et al, 2000). Hackett et al. 
also used TaqMan-PCR to track the time-dependent distribution of vectors in vivo (Hackett 
N.R. et al, 2000). These studies support the feasibility of utilizing Q-PCR to track viral 
vectors.  
3.7 In vivo imaging system (IVIS) 
In conventional experimental strategies, temporal information about biological processes is 
often obtained through repeated, time-stacked animal sacrifice. If fine temporal analysis is 
sought during the observation of key biological stages in normal development or disease, 
the number of animals required per experiment can be quite large (Christopher H.C. & 
Michael H.B., 2002). Noninvasive imaging methods enable gene expression assays to be 
conducted in living animals, and they comprise the emerging field of in vivo imaging in 
which a variety of imaging modalities are used for real-time visual monitoring and 
assessment of biological processes in living animals (Ntziachristos V., 2006). As shown in 
Fig.3, this technology greatly reduces the number of animals sacrificed per experiment 
because they allow the comprehensive assessment of each animal over the entire duration of 
the process (Contag P.R. et al., 1998; Rocchetta H.L. et al., 2001). 
Despite obvious progress in gene therapy, the recent failure of trials using adenoviral vectors 
reminds us that the use of viral vectors has risks that should be carefully assessed. What’s 
more, great the progress in viral vector production, and a better understanding of molecular 
aspects of vector delivery and targeting issues, has created the need for imaging techniques 
that could address the problems and opportunities inherent to gene therapy development.  
As noted previously, in vivo imaging could play a unique role in preclinical and clinical 
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Fig. 3. Comparison of conventional experimental strategies and Noninvasive imaging 
methods. (A) conventional experimental strategies; (B) Noninvasive imaging methods 
gene therapy research and answer the following fundamental questions asked by gene 
therapists: 
• How long would the vector reach its target after in vivo administration? 
• How many of the vectors are in the target? 
• When the expression would take place? 
• How long would the expression last? 
• Did gene transfer take place? 
There have been many recent advances in imaging research to provide answers to these 
questions mentioned above, and particularly in the utilization of such strategies for the 
distribution studies of viral vectors. The imaging technology alone, however, can only yield 
limited information, and pharmacokinetics parameters remain unclear. In this regard, more 
efforts are required to develop multi-modality imaging strategies allowing for co-
registration of high resolution anatomical data together with high sensitive molecular 
information. 
4. Challenges and prospects  
As noted previously, viral gene therapy research has evolved considerably since the first 
clinical trials of this technology. The range of therapeutic targets has also expanded from the 
treatment of monogenetic disorders to the prevention and treatment of acquired diseases, 
and so has the number and range of possible therapeutic nucleic acids. This therapeutic 
modality represents one of the most important developments to occur in medicine. On the 
other hand, certain technical problems arising from pharmacokinetic studies of viral gene 
therapy remain to be overcome.  
Design and development of ideal gene delivery vectors (Table. 2) are among the main 
challenges in the evolution of experimental gene therapy into a clinically acceptable 
mainstream therapy (Rubanyi, G.M., 2001). In spite of the relatively undemanding nature of 
the selected viral vectors in clinical trials, results from many early stage clinical trials have 
been frequently disappointing due to the inadequacy of the vectors. The main hurdle for 
successful viral gene therapy has been the host response to the gene therapy vector, the lack 
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of long-term gene expression, and problems related to the viral property of integration 
(Neeltje A. K. & Inder M. V. 2003), all of which represent the general aim of pharmacokinetic 
studies in viral gene therapies. Together, the choice of vector, the design of the expression 
cassette, and the coding sequence of the genes determine the pharmacokinetics of vectors. 
Additionally, innovations in vector design will require a better understanding of delivery 
problems, both at the level of intracellular trafficking of viral DNA to the nucleus and at the 
level of biological fluid stability and tissue penetration. Hence, much more basic research is 
needed to interpret the mechanism of viral gene therapy. 
 
Insert size capacity for one or more genes 
Targeting 
delivery to specific cell types or gene 
 expression limited to target cells 
Regulation controllable expression levels of transgenes 
Safety and stability 
safe for the patient and the environment- devoid 
 of the risk of insertional mutagenesis 
Immune response appropriate 
Titles high concentrations and stable final product 
Manufacture easy, reproducible, possible for scale-up and standardization 
Table 2. The ideal vector for gene transfer in gene therapy protocols (Dani, S.U., 1999). 
Over the past decades, the process and validation of bioanalytical methods have been well 
developed to generate pharmacokinetic data and provide ADME (absorption, distribution, 
metabolism, and elimination) information on biotech drugs. However, pharmacokinetic 
principles of viral gene therapy are far away from sufficiency in spite of long-term and 
extensive efforts, which requires more considerations when developing bioanalytical 
approaches in gene therapy with viral vectors, including validation and assay 
implementation. 
Despite recent advances in analytical techniques, further improvements in current analysis 
modalities are still at the center stage. As mentioned above, all of the technologies 
mentioned in the review have played important roles during the development of viral gene 
therapy and provided us important information. But only limited material can be obtained 
when these methods are used alone. 
Challenges including pharmacokinetic studies and analytical methods were shortly 
described above. It is evident that overcoming these barriers will contribute greatly to the 
development of viral gene therapy. 
In recent years, more attention has been paid on new viral vectors and modifying the 
existing ones to make them have less toxicity and immunity, besides, with ideal 
pharmacokinetic features. A number of strategies have evolved to enhance the targeting of 
gene transfer vectors by genetic or chemical modification on the surface of the vector. Gene 
expression directed by the transferred gene can be regulated by inducible promoters, tissue-
specific promoters, and trans-splicing. And many hybird or chinmeric vectors have 
emerged. Mizuguchi H. et al. developed adenovirus vectors containing chimeric type 5 and 
type 35 fiber proteins, which exhibit altered and expanded tropism and increase the size 
limit of foreign genes (Mizuguchi H. & Hayakawa T., 2002). Lars Mullera et al. developed 
hybrid vectors HSV–EBV (hepies-simplex-virus-epstein-barrvirus hybrid amplicons) to 
transfer genes into hepatocytes (Mullera L. et al., 2005). Goncalves MA et al. developed 
www.intechopen.com
 Viral Gene Therapy 
 
444 
AAV-Ad hybrid vectors, improving the transfer efficiency and expression duration 
(Goncalves M.A. et al., 2002). These approaches will, consequently, provide more vectors 
practicable in clinical gene therapies. 
Besides, on the basis of what mentioned above, no single modality is ideal for all possible 
applications and, thus, new protocols for pharmacokinetic studies have been developed in 
viral gene therapy. Wood M. et al. investigated the biodistribution of Ad vector following 
systemic administration with a PCR and luciferase assay (Mark Wood et al., 1999), which 
provided semi-quantitative and qualitative analyses of vector distribution. Pan D. et al. 
applied real-time PCR method and flow-cytometric analysis to measure the distribution of 
lentiviral Vector and expression of target gene in various organs (Dao Pan et al., 2002). And 
our team used TaqMan real-time PCR and in vivo imaging system to track the time-
dependent distribution of rAd5/35 in vivo post intramuscular injection. The vector was 
found to remain primarily at the injection site for about eight weeks, at which point it 
became undetectable (Fig. 4). This result was also shown by in vivo imaging of rAd5/35-luc 
in Balb/c mice (Fig. 5). What’s more, as shown in Fig. 6, the whole process of luciferase 
expression could be monitored in Balb/c mice post-injection with rAd5/35-luc. Quantitative 
and qualitative results could be attained through the utility of real-time PCR and IVIS 
technology in biodistribution study of viral gene therapy. In general, the combination of 
these two approaches provides a rapid, simple approach for a precise, visible result and will 
ultimately accelerate the progress of gene therapy studies.  
 
 
Fig. 4. Biodistribution of rAd5/35-HGEC in tissues of Balb/c mice post-injection with 
1.6×109vp 
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Fig. 5. Luciferase expression in Balb/c mice post-injection with rAd5/35-luc 
(2×1010vp)θn=5χ 
 
 
Fig. 6. Duration of luciferase expression in Balb/c mice post-injection with rAd5/35-luc 
(2×1010vp)θn=5χ. 
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The young field of viral gene therapy promises major medical progress toward the cure of  
a broad spectrum of human diseases, and has generated great hopes. To achieve this  
goal, scientists from many different disciplines should participate and pull together as a 
team. Geneticists must identify target genes while the task for the virologists is to develop 
efficient and safe vectors. Finally, clinicians carry out clinical trials with vectors optimized 
for the disease and the medical requirements of the patients (Pfeifer, A. & Verma, I.M., 
2001).  
On the whole, progress has been made in addressing many of these challenges over the past 
decades. Based on the continued focus on solving these issues, the knowledge gained from 
the successes and the setbacks will prove beneficial in viral gene therapy, and there is no 
doubt that prodigious work will result in innovative technology for pharmacokinetic 
studies.  
5. Conclusion 
Gene therapy with viral vectors has been proven very effective in a variety of model 
systems. And great progress has been made in pharmacokinetic studies of viral gene 
therapy. However, there are still many challenges, including the host response to the viral 
vectors, the lack of long-term gene expression, and the risks related to integration into the 
host genome. Thus, understanding of the pharmacokinetic behavior of viral vectors and 
developing ideal methods for pharmacokinetic studies will greatly accelerate the 
development of gene therapy. It’s believed that gene therapy has the power to become a 
dominant therapeutic modality in the future – but all in good time. 
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